| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_933e5ebbd0c9e3786b074aa9b62628f3 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2059
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-444 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2018-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_97d8df769fc80e8ce9321133c13c096e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_97d0b28bd239702228efda9f91f63aa9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5e26830ae83d6b9e5a4f1dc6c9ccfe25
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e9f73d0f4178eef5369325bf98cf25ac |
| publicationDate |
2019-05-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2019094832-A1 |
| titleOfInvention |
A combination therapy with apatinib for the treatment of cancer |
| abstract |
Provided herein are methods for the treatment of diseases, comprising administering a combination of a tyrosine kinase inhibitors and an immunotherapeutic agent. A method of treating cancer comprising administering to a patient in need thereof a therapeutically effective amount of apatinib in combination with a therapeutically effective amount of an immunotherapeutic agent. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111558044-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-4041304-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106176757-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021047623-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106176757-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112741905-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021237022-A1 |
| priorityDate |
2017-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |